Abstract
Opioid peptides and their G protein-coupled receptors (GPCRs) are important regulators within the cardiovascular system, implicated in modulation of electrophysiological function, heart rate, myocardial inotropy, vascular function, and cellular stress resistance. The opioid system is also involved in cardiovascular development, adaptation to injury and effects of advanced age. The significant roles of opioids are emphasized by the observation that the heart produces prodynorphin and proenkephalin, which are enzymatically processed from small to large active polypeptides. Indeed, depending on species, cardiac preproenkephalin mRNA levels are comparable to or higher than those found in the central nervous system. This review highlights and discusses current knowledge and recent findings regarding physiological and pathophysiological modulation of the heart and vessels by the opioid receptor system.
Keywords: Opioid peptide, opioid receptor, cardiovascular system, cytoprotection, G protein-coupled receptors (GPCRs), electrophysiological function, heart rate, myocardial inotropy, vascular function, cellular stress resistance.
Current Pharmaceutical Design
Title:Non-Analgesic Effects of Opioids: Cardiovascular Effects of Opioids and their Receptor Systems
Volume: 18 Issue: 37
Author(s): John P. Headrick, Salvatore Pepe and Jason N. Peart
Affiliation:
Keywords: Opioid peptide, opioid receptor, cardiovascular system, cytoprotection, G protein-coupled receptors (GPCRs), electrophysiological function, heart rate, myocardial inotropy, vascular function, cellular stress resistance.
Abstract: Opioid peptides and their G protein-coupled receptors (GPCRs) are important regulators within the cardiovascular system, implicated in modulation of electrophysiological function, heart rate, myocardial inotropy, vascular function, and cellular stress resistance. The opioid system is also involved in cardiovascular development, adaptation to injury and effects of advanced age. The significant roles of opioids are emphasized by the observation that the heart produces prodynorphin and proenkephalin, which are enzymatically processed from small to large active polypeptides. Indeed, depending on species, cardiac preproenkephalin mRNA levels are comparable to or higher than those found in the central nervous system. This review highlights and discusses current knowledge and recent findings regarding physiological and pathophysiological modulation of the heart and vessels by the opioid receptor system.
Export Options
About this article
Cite this article as:
P. Headrick John, Pepe Salvatore and N. Peart Jason, Non-Analgesic Effects of Opioids: Cardiovascular Effects of Opioids and their Receptor Systems, Current Pharmaceutical Design 2012; 18 (37) . https://dx.doi.org/10.2174/138161212803582360
DOI https://dx.doi.org/10.2174/138161212803582360 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Caveolin-3: Its Importance in Muscle Function and Pathology
Current Genomics Heart Failure in Chronic Myocarditis: A Role for microRNAs?
Current Genomics MicroRNA 21 Emerging Role in Diabetic Complications: A Critical Update
Current Diabetes Reviews Pathogenesis of Age-Related Cataract: A Systematic Review of Proteomic Studies
Current Proteomics Curcumin and its Multi-target Function Against Pain and Inflammation: An Update of Pre-clinical Data
Current Drug Targets Cardiac Protection via Metabolic Modulation: An Emerging Role for Incretin-Based Therapies?
Cardiovascular & Hematological Agents in Medicinal Chemistry Sympathetic Activation in Congestive Heart Failure: Evidence, Consequences and Therapeutic Implications
Current Vascular Pharmacology Advanced Glycation End Products: Association with the Pathogenesis of Diseases and the Current Therapeutic Advances
Current Clinical Pharmacology A Review of Patents on Implantable Heart-Compression/Assist Devices and Systems
Recent Patents on Biomedical Engineering (Discontinued) Old and New Gasotransmitters in the Cardiovascular System: Focus on the Role of Nitric Oxide and Hydrogen Sulfide in Endothelial Cells and Cardiomyocytes
Current Pharmaceutical Biotechnology Current Drug Nano-targeting Strategies for Improvement in the Diagnosis and Treatment of Prevalent Pathologies such as Cardiovascular and Renal Diseases
Current Drug Targets The Adenine Nucleotide Translocator: A New Potential Chemotherapeutic Target
Current Drug Targets Anticoagulation in Patients with Heart Failure
Cardiovascular & Hematological Agents in Medicinal Chemistry Cardiac MRI in Autoimmune Diseases: Where Are We Now?
Current Cardiology Reviews Cardiovascular Complications of HIV Infection and Treatment
Cardiovascular & Hematological Agents in Medicinal Chemistry Essential Roles of Toll-Like Receptors in Atherosclerosis
Current Medicinal Chemistry Antiapoptotic Effect of Novel Compound from Herba leonuri-Leonurine (SCM-198): A Mechanism Through Inhibition of Mitochondria Dysfunction in H9c2 Cells
Current Pharmaceutical Biotechnology Endothelial Dysfunction in the Hypertensive State: Mechanisms of Hypertensive Cardiovascular Complications
Current Hypertension Reviews Microvascular Function/Dysfunction Downstream a Coronary Stenosis
Current Pharmaceutical Design Conditional Cardiac Overexpression of S100A6 Attenuates Myocyte Hypertrophy and Apoptosis Following Myocardial Infarction
Current Pharmaceutical Design